Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
39.80
+0.46 (1.17%)
Nov 21, 2024, 4:00 PM EST - Market closed
Xenon Pharmaceuticals Analyst Ratings
Total Analysts
10
Consensus Rating
Strong Buy
Price Target
$57.30
Upside
+43.97%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +33.17% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +50.75% | Nov 13, 2024 |
| Raymond James | Raymond James | Buy Initiates $50 | Buy | Initiates | $50 | +25.63% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $53 | Strong Buy | Initiates | $53 | +33.17% | Oct 1, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $55 | Buy | Reiterates | $55 | +38.19% | Sep 3, 2024 |
| Needham | Needham | Strong Buy Maintains $62 → $60 | Strong Buy | Maintains | $62 → $60 | +50.75% | Aug 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +63.32% | Aug 9, 2024 |
| Wedbush | Wedbush | Buy Maintains $50 → $49 | Buy | Maintains | $50 → $49 | +23.12% | Aug 9, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $55 | Buy | Reiterates | $55 | +38.19% | Jun 18, 2024 |
| Needham | Needham | Strong Buy Maintains $62 | Strong Buy | Maintains | $62 | +55.78% | May 10, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $62 → $60 | Strong Buy | Maintains | $62 → $60 | +50.75% | May 10, 2024 |
| Wedbush | Wedbush | Buy Maintains $51 → $50 | Buy | Maintains | $51 → $50 | +25.63% | May 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $62 | Strong Buy | Reiterates | $62 | +55.78% | Apr 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +63.32% | Apr 10, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $56 → $55 | Buy | Maintains | $56 → $55 | +38.19% | Mar 1, 2024 |
| Wedbush | Wedbush | Buy Maintains $46 → $51 | Buy | Maintains | $46 → $51 | +28.14% | Mar 1, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.